Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study.

scientific article

Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.EURPSY.2011.06.009
P698PubMed publication ID21920710

P50authorMarianne HaapeaQ38640138
Jouko MiettunenQ38640161
Hannu KoponenQ44571789
P2093author name stringJ Veijola
M Isohanni
E Jääskeläinen
J Moilanen
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectFinlandQ33
schizophreniaQ41112
birth cohortQ64532946
P304page(s)53-58
P577publication date2011-09-14
P1433published inEuropean PsychiatryQ5413047
P1476titleCharacteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study.
P478volume28

Reverse relations

cites work (P2860)
Q38708602A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia
Q38233228A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy
Q97521512Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder
Q38592404Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia
Q64925081Factors Associated With Successful Medication Discontinuation After a Randomized Clinical Trial of Relapse Prevention in First-Episode Psychosis: A 10-Year Follow-up.
Q30835228Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort
Q55360200Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period?
Q50527605Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis.
Q64068715Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders
Q47755626Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up
Q50205158Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study
Q35382798The 4th Schizophrenia International Research Society Conference, 5-9 April 2014, Florence, Italy: a summary of topics and trends
Q38570636The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
Q90728397The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia
Q96773916The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
Q35673737Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review
Q55339046Under-utilized opportunities to optimize medication management in long-term treatment of schizophrenia.
Q89669017Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs
Q38664662Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.
Q55023835What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Search more.